Knut Engels

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani et al. · The Lancet Oncology · 2017 · 2K citations

Breast Oncology, Neoadjuvant Therapy, Medicine +9

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Carsten Denkert, Sibylle Loibl, Aurelia Noske et al. · Journal of Clinical Oncology · 2009 · 1.8K citations

Breast Oncology, Immunology, Pathology +17

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Gbg 66, Breast Oncology, Medicine +7

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 666 citations

Clinical Results, Breast Oncology, Biomarker Analysis +7

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers

Achim Rody, Uwe Holtrich, L. Pusztai et al. · Breast Cancer Research · 2009 · 476 citations · Full text